Cargando…

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer

SIMPLE SUMMARY: Prostate cancer is currently the fifth leading cause of death in men worldwide. To personalize and guide treatment in prostate cancer, identification of druggable genomic alterations is of major importance. Prostate cancer often metastasizes solely or predominantly to the bones, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smits, Minke, Ekici, Kamer, Pamidimarri Naga, Samhita, van Oort, Inge M., Sedelaar, Michiel J. P., Schalken, Jack A., Nagarajah, James, Scheenen, Tom W. J., Gerritsen, Winald R., Fütterer, Jurgen J., Mehra, Niven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764855/ https://www.ncbi.nlm.nih.gov/pubmed/33327413 http://dx.doi.org/10.3390/cancers12123756

Ejemplares similares

(68)Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients
por: van Steenbergen, T. R. F., et al.
Publicado: (2019)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2020)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Research Highlight: (68)Ga-PSMA-11 PET Imaging for Pelvic Nodal Metastasis in Prostate Cancer
por: Fütterer, Jurgen J., et al.
Publicado: (2022)

PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
por: Banda, Amina, et al.
Publicado: (2022)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
por: Leyten, Gisele H. J. M., et al.
Publicado: (2013)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

The need for a personalized approach for prostate cancer management
por: Sedelaar, JP Michiel, et al.
Publicado: (2015)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB
por: Venderink, Wulphert, et al.
Publicado: (2018)

Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation
por: Peters, Steffie M. B., et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment
por: Peters, Steffie M. B., et al.
Publicado: (2021)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma
por: Tolmeijer, Sofie H., et al.
Publicado: (2021)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Probing single-cell metabolism reveals prognostic value of highly metabolically active circulating stromal cells in prostate cancer
por: Rivello, Francesca, et al.
Publicado: (2020)

Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2021)

PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery
por: Derks, Yvonne H.W., et al.
Publicado: (2019)

Intra-therapeutic dosimetry of [(177)Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
por: Peters, Steffie M. B., et al.
Publicado: (2021)

Implementation of a Technique Based on Hounsfield Units and Hounsfield Density to Determine Kidney Stone Composition
por: Rodríguez-Plata, Irvin Tadeo, et al.
Publicado: (2021)

Lactate dehydrogenase: a marker of diminished antitumor immunity
por: Van Wilpe, Sandra, et al.
Publicado: (2020)

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis
por: Luna Velez, Maria V., et al.
Publicado: (2019)

Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
por: van Wilpe, Sandra, et al.
Publicado: (2020)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer
por: Derks, Yvonne H.W., et al.
Publicado: (2021)

The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
por: Benoist, Guillemette E., et al.
Publicado: (2020)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes
por: Overduin, Christiaan G., et al.
Publicado: (2017)

The Effect of Higher Level Computerized Clinical Decision Support Systems on Oncology Care: A Systematic Review
por: Klarenbeek, Sosse E., et al.
Publicado: (2020)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited
por: Cremers, Ruben G., et al.
Publicado: (2016)

The effect of eating on the uptake of PSMA ligands in the salivary glands
por: Mohan, V., et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide
por: Podgoršek, Eva, et al.
Publicado: (2023)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sponbesmjumberal32s9n3hq5u